ClinicalTrials.gg
CompletedNCT03722823Updated May 20, 2019

A Safety Study of Tucatinib in Healthy and Hepatically-Impaired Subjects

A Phase 1 interventional study of Tucatinib in Hepatic Impairment, sponsored by Seagen Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-05-20.

Sponsored by Seagen Inc. (part of Pfizer) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2019, 7 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
37
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The investigators are doing this study to find out if tucatinib is safe for patients with liver problems. This study will look at participants with mild, moderate, and severe liver problems. For each participant with liver problems who takes part, a matching healthy participant who is of similar age, similar body mass index (BMI), and of the same sex will also take part. The study will look at how the drug affects healthy participants compared to participants with liver problems.

Read the detailed description

This study is being conducted to provide information to develop dosing recommendations for tucatinib in subjects with hepatic impairment. The current study will be carried out in subjects with hepatic impairment according to 3 different Child-Pugh (CP) categories (Mild, Moderate, and Severe impairment), and in matched-control healthy subjects. The minimum number of matched-control healthy subjects will be enrolled in order to ensure that each hepatically-impaired subject has a healthy match. Each matched-control healthy subject will be enrolled following the enrollment of a Mild and/or Moderate and/or Severe hepatic impairment subject and will be matched by age (+/- 10 years), by BMI (+/- 20%), and by sex to the enrolled hepatic impairment subject(s). Each healthy subject may be matched with up to 1 subject within each hepatic impairment group. Based on these criteria, with 3 cohorts of 8 hepatically-impaired subjects enrolled in the study, the number of healthy control subjects required to be enrolled will be at least 8 and not more than 24.

02

Conditions studied

  • Hepatic Impairment
03

In context

Lead sponsor

Seagen Inc. is the lead sponsor of 88 studies on the registry; 1 is open to participants now.

Of its 27 completed or terminated interventional studies of FDA-regulated products, 14 (52%) have results posted.

First submitted before Seagen Inc. became part of Pfizer.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • In good general health, except for additional inclusion criteria related to subjects with hepatic impairment
  • Within (BMI) range of 18 to 37 kg/m\^2 (inclusive)
  • Males capable of fathering a child must agree to use from check in through 90 days after dose administration
  • Females must be of nonchildbearing potential
  • Able to understand and provide written
  • Able to comply with all study procedures, including the 3-night stay at the clinical site and follow-up phone call
  • Healthy subjects only: matched to subjects with Mild and/or Moderate and/or Severe hepatic impairment in sex, age (+/- 10 years), and BMI (+/- 20%).
  • Hepatic impairment subjects only: considered to have Mild, Moderate, or Severe hepatic impairment that has been clinically stable for at least 1 month
  • Hepatic impairment patients only: currently on stable medication regimen

Exclusion criteria

Exclusion Criteria:

  • Subjects with at-rest vital signs outside of the following ranges: heart rate (40 to 120 bpm), systolic blood pressure (90 to 150 mmHg), diastolic blood pressure (40 to 95 mmHg)
  • abnormal laboratory values or physical examination findings
  • Evidence/history of long syndrome
  • Use of drugs/substances known to be inhibitors or inducers of or CYP2C8 enzyme within 30 days
  • Consumption of foods or beverages containing poppy seeds, grapefruit, or Seville oranges within 7 days of check-in
  • Consumption of alcohol-, citric acid-, caffeine-, or xanthine-containing foods or beverages within 48 hours prior to check in
  • Subjects with known alcohol and/or drug abuse within 1 month prior to check in
  • History of significant , intolerance, or allergy to any drug compound, food, or other substance
  • History of congenital nonhemolytic hyperbilirubinemia
  • History of stomach or intestinal surgery that would potentially alter absorption and/or excretion of orally administered drugs
  • Prior doses of tucatinib
  • Prior dose of any drug within the past 30 days or 5 half-lives
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Active comparator
    Group 1: Healthy

    Match-controlled healthy subjects with normal hepatic function

    Drug: Tucatinib

  • Experimental
    Group 2: Mild Hepatic Impairment

    Subjects with Mild hepatic impairment (Child-Pugh Class A, score of 5 or 6)

    Drug: Tucatinib

  • Experimental
    Group 3: Moderate Hepatic Impairment

    Subjects with Moderate hepatic impairment (Child-Pugh Class B, score of 7 to 9)

    Drug: Tucatinib

  • Experimental
    Group 4: Severe Hepatic Impairment

    Subjects with Severe hepatic impairment (Child-Pugh Class C, score of 10 to 14)

    Drug: Tucatinib

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum observed concentration (Cmax)

    Pharmacokinetic (PK) endpoint of tucatinib

    Time frame: Up to 48 hours

  2. Time of maximum observed concentration (Tmax)

    PK endpoint of tucatinib

    Time frame: Up to 48 hours

  3. Area under the concentration-time curve (AUC) from time 0 to the last quantifiable concentration (AUC[0-t])

    PK endpoint of tucatinib

    Time frame: Up to 48 hours

  4. AUC from time 0 to infinity (AUC[0-inf])

    PK endpoint of tucatinib

    Time frame: Up to 48 hours

  5. Percentage extrapolation for AUC (%AUCextrap)

    PK endpoint of tucatinib

    Time frame: 48 hours

  6. Apparent terminal elimination rate constant (λz)

    PK endpoint of tucatinib

    Time frame: Up to 48 hours

  7. Apparent terminal elimination half-life (t½)

    PK endpoint of tucatinib

    Time frame: Up to 48 hours

  8. Apparent total clearance

    PK endpoint of tucatinib

    Time frame: Up to 48 hours

  9. Apparent volume of distribution during the terminal phase

    PK endpoint of tucatinib

    Time frame: Up to 48 hours

  10. Mean residence time (MRT)

    PK endpoint of tucatinib

    Time frame: Up to 48 hours

Secondary outcomes

  1. Cmax

    PK endpoint of ONT-993

    Time frame: Up to 48 hours

  2. Tmax

    PK endpoint of ONT-993

    Time frame: Up to 48 hours

  3. AUC[0-t]

    PK endpoint of ONT-993

    Time frame: Up to 48 hours

  4. (AUC[0-inf])

    PK endpoint of ONT-993

    Time frame: Up to 48 hours

  5. %AUCextrap

    PK endpoint of ONT-993

    Time frame: Up to 48 hours

  6. λz

    PK endpoint of ONT-993

    Time frame: Up to 48 hours

  7. t½

    PK endpoint of ONT-993

    Time frame: Up to 48 hours

  8. MRT

    PK endpoint of ONT-993

    Time frame: Up to 48 hours

  9. Incidence of adverse events (AEs)

    As determined by assessment of AEs, clinical laboratory tests, physical examinations, vital signs measurements, and 12-lead ECG

    Time frame: Up to 9 days

07

Study locations

4 sites
  • Orange County Research Center
    Tustin, California 92780, United States
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
  • NOCCR Knoxville and Volunteer Research Group
    Knoxville, Tennessee 37920, United States
  • Texas Liver Institute
    San Antonio, Texas 78215, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2018 to primary completion in May 2019, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2018
First posted
Oct 29, 2018
StartActual
Oct 10, 2018
Primary completionActual
May 7, 2019
CompletionActual
May 7, 2019
Last update
May 20, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03722823
Lead sponsor
Seagen Inc.
Responsible party
Sponsor
First posted
Oct 29, 2018
Start date
Oct 10, 2018
Primary completion
May 7, 2019
Completion
May 7, 2019
Last update
May 20, 2019

Study contacts

Joseph Woolery, PharmD, BCOP
study director · Seagen Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tucatinib

Start the discussion